GREENWOOD VILLAGE, Colo., Nov. 28, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. ( AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced the appointment of Josh Disbrow as Chief Operating Officer of Ampio Pharmaceuticals, effective December 15, 2012.
Mr. Disbrow was most recently the Vice President of Commercial Operations at Arbor Pharmaceuticals. He joined Arbor in 2007 as the company's second full time employee and led the company's commercial efforts from inception to $127 million in annual sales in 2011 at which time the company was sold to an investor group. Since the company's acquisition, Josh remained with Arbor and oversaw the growth of the company's commercial infrastructure to over 150 people in sales, marketing, and other commercial functions. During his time at Arbor, Josh also served as the company's commercial lead on all business and corporate development activities including in-licensing, out-licensing, partnering, mergers and acquisitions, and university collaborations.Arbor began as an entrepreneurial venture with no products on the market. Through Josh's leadership Arbor developed into a fully integrated specialty pharmaceutical company with a focus on bringing novel prescription pharmaceuticals to market through efficient product development, aggressive business development, corporate partnerships, and efficient commercial scale-up. Mr. Disbrow has spent 17 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations, and commercial strategy. Before joining Arbor, he was in sales management with Cyberonics, Inc., a medical device company focused on neuromodulation therapies. Prior to joining Cyberonics, Josh served as Director of Marketing at LipoScience, Inc., a specialty diagnostics company and oversaw commercialization of the company's lead product. Josh began his career at Glaxo Welcome (now GlaxoSmithKline) where he held positions of increasing responsibility within sales and marketing divisions. Josh received an MBA from Wake Forest University and a BS in Management from North Carolina State University. Mr. Disbrow stated, "I am excited to be joining the management team at Ampio. Ampio has made significant progress in advancing their lead drugs towards commercialization in a short period of time, and I look forward to bringing my experience and enthusiasm to the team. The Ampio story is compelling, and I hope to play a significant role in helping the company complete their pivotal clinical trials and achieve successful commercial launches of their lead drugs in the near future."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV